Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer

Sequential chemotherapy may improve treatment efficacy avoiding the additive toxicity associated with concomitant polichemotherapy in hormone-refractory prostate cancer (HRPC). Forty patients received docetaxel 30 mg m(−2) intravenous (i.v.), weekly, plus estramustine 280 mg twice daily for 12 weeks...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Galli, L, Fontana, A, Galli, C, Landi, L, Fontana, E, Antonuzzo, A, Andreuccetti, M, Aitini, E, Barbieri, R, Di Marsico, R, Falcone, A
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2007
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360275/
https://ncbi.nlm.nih.gov/pubmed/18026196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604090
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires